Medicure Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPH.V research report →
Companywww.medicure.com
Medicure Inc. , a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
- CEO
- Albert David Friesen
- IPO
- 2012
- Employees
- 25
- HQ
- Winnipeg, MB, CA
Price Chart
Valuation
- Market Cap
- $12.52M
- P/E
- -1.76
- P/S
- 0.43
- P/B
- 0.97
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 40.71%
- Op Margin
- -23.87%
- Net Margin
- -24.60%
- ROE
- -41.37%
- ROIC
- -49.91%
Growth & Income
- Revenue
- $28.86M · 31.72%
- Net Income
- $-7,097,000 · -583.06%
- EPS
- $-0.68 · -582.73%
- Op Income
- $-6,888,000
- FCF YoY
- -187.77%
Performance & Tape
- 52W High
- $1.43
- 52W Low
- $0.85
- 50D MA
- $1.13
- 200D MA
- $1.15
- Beta
- 0.97
- Avg Volume
- 1.31K
Get TickerSpark's AI analysis on MPH.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MPH.V Coverage
We haven't published any research on MPH.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MPH.V Report →